Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

2.655 -0.015 (-0.56%)
Streaming Delayed Price Updated: 10:37 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,323
Open 2.620
Bid (Size) 2.600 (300)
Ask (Size) 2.710 (100)
Prev. Close 2.670
Today's Range 2.620 - 2.850
52wk Range 1.300 - 3.190
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adagene Provides Business Update and 2026 Objectives
From Adagene Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill

Performance

YTD
+44.3%
+44.3%
1 Month
+67.0%
+67.0%
3 Month
+68.0%
+68.0%
6 Month
+15.9%
+15.9%
1 Year
+56.2%
+56.2%

More News

Read More
News headline image
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
From Adagene Inc.
Via GlobeNewswire
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Participate in Two Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
From Adagene Inc.
Via GlobeNewswire
News headline image
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene announces up to $25 million strategic investment from Sanofi
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Present at Jefferies Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
From Adagene Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 2.655
When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 02/10/26 10:37 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS